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Tumor necrosis factor (TNF)- induces pleiotropic cellular α
effects through a 55kDa, type 1 receptor (TNFR1) and a
75kDa type 2 receptor (TNFR2). Moreover, it participates in
the pathogenesis of several CNS diseases, including demyeli-
nating diseases. TNF- receptors are differentially expressed α
and are regulated in many cell types. However, data regarding
the TNF- receptor expression and regulation in human astro α -
cytes is limited to date. We investigated TNF- receptor ex α -
pression, its regulation by cytokines, and its functional role in
primary cultured human fetal astrocytes, which are the most
abundant cellular population in the central nervous system and
are known to be immunologically active. In this study, astro-
cytes were found to constitutively and predominantly tran-
scribe, translate and shed TNFR1 rather than TNFR2, but
TNFR2 expression was increased by adding TNF- , IL-1, and α
IFN- , but not by adding LPS. To determine the functional γ
roles of TNFR1 and TNFR2 on TNF induction, we investi-
gated NF- B activation and TNF- induction after neutralizing κ α
TNFR1 and TNFR2 by an antibody treatment. We found that
NF-kB activation and TNF- induction are blocked by TNFR1 α
neutralizing antibody treatments.
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INTRODUCTION
The central nervous system (CNS) has been
considered as an immune-privileged site. How-
ever, recent studies have shown that resident cells
of the CNS, including astrocytes, microglia, oligo-
dendrocytes, and neurons actively participate in
ongoing immune responses in the CNS.
1-3 Astro-
cytes are the most abundant glial cell type in the
CNS and have been shown to produce and
respond to cytokines. Such cytokines include
tumor necrosis factor (TNF)- , interleukin-1 (IL-1), α
granulocyte macrophage colony-stimulating factor
(GM-CSF), transforming growth factor (TGF),
IL-10, and IL-12 as well as chemokines.
4-8 Some of
these cytokines, such as TNF- , have shown in α -
volvement in immune-mediated CNS disorders,
including multiple sclerosis (MS) and experimen-
tal allergic encephalomyelitis (EAE). They are in-
volved in ways that promote the infiltration of
inflammatory cells into the CNS, intracerebral im-
mune responses, cytokine production, astrogliosis,
and demyelination.
9-11 However, several experi-
ments have demonstrated that TNF- has neuro α -
protective actions. The dual action of TNF- in the α
CNS may be determined by which types of
signaling pathways, proapoptotic or antiapoptotic,
are activated through TNF- and TNF receptor α
interaction.
The induction of various cellular responses
mediated by TNF- is initiated by its interaction α
with two distinct cell surface receptors of approxi-
mately 55kDa (TNFR1) and 75kDa (TNFR2).
12
While the extracellular domains of these two
receptors exhibit some sequence homology, their
intracellular or cytoplasmic domains appear quite
dissimilar.
13,14 This is thought to be indicative of
the existence of distinct signaling pathways.
Recent studies have indicated that TNFR1
mediates the signals required for cytotoxicity and
other TNF- activities, including antiviral activity, α
fibroblast proliferation, and the induction of NF-
κB, while TNFR2 is involved in signaling the
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proliferation of thymocytes, cytotoxic T cells, and
human mononuclear cells.
15-17
Several cytokines have been shown to regulate
TNFR1 and TNFR2 expression in a variety of
cells.
18-21 The modulation of TNFR expression by
inflammatory cytokines may represent a means of
controlling the responsiveness of TNF- . α
TNF- has multiple effects on astrocytes, such α
as increasing intracellular Ca
2+ and depolarization,
and inducing multiple cytokines and adhesion
molecules.
22 Upon its activation, TNF- induces α
TNF- secretion in an autocrine fashion. α
23 More-
over, TNF- has been shown to induce cell proli α -
feration in astrocytes.
24,25
Conflicting results exist regarding the expres-
sions of TNFR1, TNFR2, and their functions in
astrocytes. Alanguez et al. reported that murine
astrocytes express only TNFR1.
26 However, a re-
cent study found that TNF- can induce TNFR2 α
gene expression, and provided a possible explana-
tion of the proliferative effect of TNF- in rat α
primary astrocytes.
27
Little is known about the cell surface expres-
sions of TNFR1 and TNFR2, and about their func-
tions in human astrocytes. Moreover, no study has
yet examined the regulations of TNFR1 and TNFR
2 expression by cytokines in human astrocytes.
In this study, we determined the expression
levels of TNFR1 and TNFR2 in human fetal astro-
cytes. We also examined the effects of the inflam-
matory cytokines IFN- , IL-1 , TNF- and bacte γ β α -
rial LPS on the expressions of TNFR1 and TNFR2
mRNA in human fetal astrocytes. Soluble TNFR1
and TNFR2 were studied using an enzyme-linked
immunosorbent assay (ELISA). Furthermore, we
have tried to identify the receptor subtype in-
volved in the induction of NF-κB activation and
TNF- production in human fetal astrocytes. α
MATERIALS AND METHODS
Cell cultures
Human fetal astrocyte cultures were prepared
as previously described.
28,29 Briefly, human fetal
brain tissue from therapeutically aborted fetuses
of gestational ages between 16 and 24 weeks was
minced and passed through a 19-gauge needle.
Cells were plated in Dulbecco's modified Eagle
medium (Gibco) containing 10% fetal bovine
serum (Gibco), 2 mM glutamine, non-essential
amino acids, penicillin/streptomycin and anti-
mycotics. Cells were passaged for three to six
weeks prior to use. Astrocyte purity was assessed
by staining for glial fibrillary acidic protein
(GFAP, Boehringer Mannheim), an astrocyte-
specific protein; the astrocyte cultures were com-
posed of more than 95% GFAP (+) cells. Primary
cultures from at least 10 different donors were
used for these studies. Each experiment was re-
peated at least three times with cells from dif-
ferent donors. THP-1 human monocytic cell lines
were obtained from ATCC and cultured in DMEM
containing 10% fetal bovine serum (Gibco).
Reagents
Lipopolysaccharide and human recombinant
IFN- were purchased from Sigma, and human γ
recombinant IL-1 and TNF- were obtained from β α
Promega and Endogen, respectively. Neutralizing
anti-human TNFR1 and anti-human TNFR2 anti-
bodies were purchased from R & D Systems, as
were ELISA Kits for soluble TNFR1 and TNFR2.
RNA isolation and competitive RT-PCR
Total cellular RNA was isolated from confluent
monolayers of human fetal astrocytes that had
been incubated with various cytokines. RNA was
isolated using a Trizol reagent (Gibco), and the
amount of RNA obtained was determined by
spectrophotometry.
Reverse transcription was performed using 1 g μ
of total RNA with oligo (dT) 12-18, AMV reverse
transcriptase (Promega), RNase inhibitor (Pro-
mega) and dNTP mix in a final volume of 20 L. μ
The mixture was incubated at 42 for 1 h and the
reaction was terminated at 95 for 5 min. RT-
PCR was performed with an automatic thermo-
cycler (Hybaid). The following primers were used:
5'-AAATGGGTCAGGTGGAGATC-3' (forward),
5'-GGCTTAGTAGTAGTTCCTTC-3' (reverse) for
TNFR1; 5'-CTCCAACACGACTTCATCCA-3' (for-
ward), 5'-GACACAGTTCACCACTCCTA-3' (re-
verse) for TNFR2; 5'-ACCACAGTCCATGCATC
AC-3' (forward), 5'-TCCACCACCCTGTTGCTGTA-Sun Ju Choi, et al.
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3' (reverse) for GAPDH; and 5'-GAGTGACAAGC
CTGTAGCCCATGTTGTAGCA-3' (forward), 5'-G
CAATGATCCCAAAGTAGACCTGCCCAGAC-3'
(reverse) for TNF- . For competitive RT-PCR, a α
known amount of a DNA competitor was added
to the PCR reaction mixture. The DNA compe-
titors were constructed using a DNA competitor
kit (Takara), which was designed to be amplified
by the same primers as the target cDNA, and
which yielded a distinguishable size of PCR
product. RT-PCR assays were performed three
times and representative results are shown.
GAPDH was used as an internal control.
Preparation of nuclear extracts
Human fetal astrocytes were stimulated with
TNF- (100 α U/mL) for 30 min, and the nuclear
extracts were prepared.
30 Briefly, cells were har-
vested by scraping and then pelleted. Next the
cells were resuspended in 1 mL of buffer A (10
mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM dithiothreitol, 1 mM phen-
ylmethylsulfonyl fluoride, and 10 g/mL of leu μ -
peptin and aprotinin), and incubated on ice for
10 min. The cells were then lysed using 0.6%
NP-40, and a nucleus pellet was obtained. The
nucleus pellets were resuspended in 30 L of μ
hypertonic buffer C (20 mM HEPES, pH 7.9, 0.4
M NaCl, 1 mM DTT, 1 mM PMSF, 1 g/mL of μ
leupeptin and aprotinin) and the nuclear extracts
were obtained. The concentration of nuclear
protein was determined using the Bio-Rad pro-
tein assay.
Electrophoretic mobility shift assay (EMSA)
NF-κB activation was determined by electro-
phoretic mobility shift assay using the method
described by Chaturvedi et al.
31 Briefly, 8 g of μ
nuclear extracts were incubated for 15 min with
or without a competitor in the binding buffer (10
mM Tris, pH 8.0, 0.075 mM KCl, 10% glycerol, 0.1
mM EDTA, 2.5 mM MgCl2, and 1 g of poly dI/ μ
dC).
32P-end-labeled double stranded NF-κB
binding oligonucleotide, 5'-AGTTGAGGGGACTT
TCCCAGGC-3', was added to the reaction mix-
ture and incubated on ice for an additional 30
min. The reaction mixtures were then resolved by
electrophoresis. Dried gels were exposed to X-ray
film (Kodak) at -70 , and the specificity of bind-
ing was examined by competition with the
unlabeled oligonucleotide.
Preparation of cellular extracts
To assess the intracellular protein level of
TNFR1 and TNFR2, cellular extracts were pre-
pared using a modification of the method of
Dignam et al.
30 After stimulation, the cells were
washed with ice-cold phosphate buffered saline,
harvested, and resuspended on ice in 300 L of μ
buffer A for 10 min. The cells were then lysed
using buffer C containing 0.1% of NP-40, and the
cellular extracts were obtained. The collected
cellular extracts were stored at -70 until use, and
protein concentrations were determined using a
Bio-Rad protein assay.
Enzyme linked immunosorbent assay (ELISA)
Immunoreactive TNFR1 and TNFR2 protein
levels were measured using TNF1 and TNFR2
Quantikine kits in accordance with the manufac-
turers' instructions (R & D Systems). All standards
and samples were assayed in triplicate and the
values were averaged. The assays were sensitive
to TNFR1 and TNFR2 levels of > 7.8 pg/mL.
RESULTS
Steady state levels of TNFR1 and TNFR2 mRNA
and protein in human fetal astrocytes
Steady state levels of TNFR1 and TNFR2
mRNAs were assessed by competitive RT-PCR on
unstimulated astrocytes. The mRNA for TNFR1
was constitutively expressed at a higher level
(equivalent to 1000 copies of competitor, Fig. 1)
than the TNFR2 transcripts (equivalent to 10
copies of competitor, Fig. 1). In addition to the
mRNA level, the levels of intracellular TNFR1 and
TNFR2 proteins were also determined by ELISA,
and it was found that TNFR1 protein was consti-
tutively expressed on unstimulated astrocytes
(127.3 ± 6.3 pg/mL) and that TNFR2 was ex-
pressed at barely detectable levels (< 7.8 pg/mL).TNF Receptor p55 is Constitutively Expressed and Dominantly Functions in Human Fetal Astrocytes
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Expressions of TNFR1 and TNFR2 after treatment
with TNF- , IL-1 IFN- and LPS in human fetal α β γ
astrocytes
To determine the effects of TNF- , IL-1 IFN- α β γ
and LPS on the relative levels of TNFR1 and
TNFR2 mRNA transcription, each reagent was
added to the culture media up to a final concen-
tration of 100 U/mL. The cultures were incubated
in the presence of reagents for 2, 4, 8, 12, 16, and
24 h at 37 . Total RNA was then isolated from
the cells and competitive RT-PCR was performed
as described above. PCR products were subse-
quently quantified using a densitometer and the
relative changes in TNFR2 specific mRNA were
calculated after normalizing the data to the
GAPDH mRNA levels. TNF- , IL-1 , and IFN- α β γ
induced an increase in TNFR2 mRNA in
astrocytes, as shown by the competitive RT-PCR
(Fig. 2). The increase in TNFR2 mRNA was
evident at 2 h post-challenge, gradually increased
thereafter, and remained elevated at 24 h.
However, the relative level of TNFR2 mRNA in
the astrocytes did not show any significant change
after LPS treatment versus the untreated control
culture. TNFR1 mRNA also did not demonstrate
any significant change after TNF- , IL-1 , IFN- , α β γ
or LPS treatment (Fig. 2).
TNFR1 was constitutively shedded in unstimu-
lated human astrocytes
Soluble TNFR1 and soluble TNFR2 were mea-
sured in the supernatant of human astrocyte
Fig. 1. Quantitation of TNFR1 and TNFR2 mRNA expres-
sions in human fetal astrocytes. Total RNA was isolated
from astrocytes and THP-1 cells using a Trizol reagent.
TNFR1 and TNFR2 mRNA levels were analyzed by
competitive RT-PCR and calculated using densitometry.
Different copies (10-10
4) of competitors were used in
competitive RT-PCR. Experiments were performed using
at least three different batches of human fetal brain
samples.
Fig. 2. Effects of TNF- , IL-1 , IFN- or LPS on TNFR1 and α β γ
TNFR2 mRNA expression in human astrocytes. Human
astrocytes were cultured in the presence or absence of
TNF- (A), IL-1 (B), IFN- (C) or LPS (D). At different α β γ
time intervals, the total RNA was isolated. Then, TNFR1
and TNFR2 mRNA levels were analyzed by competitive
RT-PCR. One thousand copies of TNFR1 competitor and
10 copies of TNFR2 competitor were used in these ex-
periments. This photograph was obtained from at least
three repetitive experiments.
Copy numbers of competitor A
B
C
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cultures. Astrocytes were trypsinized and plated
in a 24 well plate. After 24-48 hours the culture
media was changed and the cells were harvested
at 1, 6, 12, 24, 36, 48, 60, and 72 h. Soluble TNFR1
and sTNFR2 levels in the culture supernatant
were determined using ELISA. The level of immu-
noreactive sTNFR1 increased steadily through the
72 hour period (1.5±0.7 pg/mL 265 ± 11.4 pg/
mL, Fig. 3), whereas the amount of sTNFR2 did
not show any significant change (< 4.5±0.56 pg/
mL, Fig. 3).
Blocking TNFR1 results in the neutralization of
the effect of TNF- on NF- α κB activation
In addition to TNF receptor mRNA expression,
we examined the functional roles of the receptors.
To determine which receptor was responsible for
NF- B activation, we used neutralizing antibodies κ
against TNFR1 and TNFR2. Cultures were incu-
bated in the presence of antibodies for 1 h. After
the removal of the media, new media containing
100U/mL of TNF- was added. Thirty minutes α
later, nuclear extracts were harvested, and EMSA
was performed using a 22 bp oligonucleotide.
Nuclear extracts from the TNF- stimulated cells α
showed a strong DNA-protein complex compared
with the unstimulated astrocytes (Fig. 4). Neutral-
izing antibodies against TNFR1 decreased the
level of the DNA-protein complex induced by
TNF- (Fig. 4). However, neutralizing antibodies α
against TNFR2 did not affect the complex for-
mation (Fig. 4).
TNFR1 blocking results in the neutralization of
the TNF- effects on TNF- induction in astrocytes α α
To determine which receptors consistently show
major functioning, we examined the effects of
neutralizing antibodies on TNF- mRNA expres α -
sion as induced by TNF- . Cultures were treated α
with antibodies for 1 h and then stimulated with
TNF- for 2 h. After total RNA isolation, RT-PCR α
was performed. TNF- mRNA was not observed α
in unstimulated astrocytes, but the astrocytes that
Fig. 3. Soluble TNFRs secretion in human astrocytes.
Human astrocytes were cultured with DMEM, and the
culture supernatants were harvested at 6, 12, 24, 36, 48, 60,
and 72 h. The levels of soluble TNFRs in the culture
supernatants were measured using ELISA. Values re-
present the means of at least three experiments.
Fig. 4. TNFR1 blocking antibody inhibits TNF- depen α -
dent NF-κB activation in human astrocytes. Human
astrocytes were preincubated for 1 h with TNFR1 (5 g/ μ
mL or 0.5 g/mL) or TNFR2 blocking antibodies (5 μ g/ μ
mL), and then treated with TNF- (100 α U/mL) for 30 min
at 37°C. The cells were then examined for NF-κB
activation by using an electrophoretic mobility shift
assay.
Fig. 5. TNFR1 blocking antibody inhibits TNF- depen α -
dent TNF- mRNA induction in human astrocytes. α
Human astrocytes were preincubated for 1 h with TNFR1
(5 g/mL) or TNFR2 (5 μ g/mL) blocking antibodies and μ
treated with TNF- (100 α U/mL) for 2 h at 37°C. RT-PCR
was done using TNF- primer. αTNF Receptor p55 is Constitutively Expressed and Dominantly Functions in Human Fetal Astrocytes
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were stimulated by TNF- showed TNF- mRNA α α
expression. Neutralizing antibodies against TNFR
1 blocked the induction of TNF- mRNA expres α -
sion by TNF- . However, neutralizing antibodies α
against TNFR2 did not affect this induction of
TNF- (Fig. 5). α
DISCUSSION
The present experiment determined the relative
mRNA levels and the protein levels of TNFR1 and
TNFR2 in primary cultured human fetal astro-
cytes. From our RT-PCR studies, it is evident that
both TNFR1 and TNFR2 mRNAs co-existe in
human astrocytes. However, we found that
TNFR1 mRNA is constitutively expressed at
higher levels than the transcripts for TNFR2.
Conflicting results have been reported regarding
the expression of TNFR1 and TNFR2 in astrocytes.
Dopp et al. reported that astrocytes expressed
only TNFR1,
32 whereas Lung et al. reported that
TNFR1 and TFNR2 were co-expressed in rat
astrocytes.
27 Moreover, Tada et al. reported that
TNFR1 and TNFR2 were co-expressed in human
astrocytes.
33 This discrepancy may be due to either
the experimental method or the difference in
species. We used competitive RT-PCR to quantify
the mRNA expressions of TNFR1 and TNFR2. The
obtained RT-PCR results demonstrated that
TNFR1 mRNA was equivalent to 1000 copies of
the TNFR1 competitor and that TNFR2 mRNA
was equivalent to 10 copies of TNFR2 competitor
in unstimulated human astrocytes. These results
suggest that, although TNFR1 and TNFR2
mRNAs co-exist, TNFR1 mRNA is dominantly
transcribed in human astrocytes. However, it is
not clear that all of the TNFR1 and TNFR2 tran-
scripts are translated into proteins in astrocytes.
Therefore, we examined the intracellular protein
levels of TNFR1 and TNFR2 by ELISA. As was the
case for mRNA expression, relatively high levels
of TNFR1 protein were detected (127.3 ± 6.3 pg/
mL), whereas the levels of TNFR2 protein were
undetectable (< 7.8 pg/mL). Surely, TNF receptor
mRNA levels and intracellular protein levels may
not correlate exactly with the surface TNF recep-
tor. In fact, both TNFR1 and TNFR2 were very
weakly detected on the cellular surfaces stained
with immunofluorescence-labeled antibodies (data
not shown). The difference between the intra-
cellular level and the surface level of TNFR1 may
arise from the intracellular remains of translated
TNFR1 or from the extracellular shedding of
membrane TNFR1.
Cellular activation by agents, such as LPS, and
TNF- , induces the rapid shedding of membrane α
TNFR in different types of cells by proteolytic
cleavage of the cell surface receptors. As a result,
soluble TNFR1 and sTNFR2 are generated.
34,35
These soluble receptors have been shown to
bind TNF- with high affinity, α
36 and the shedding
of TNF receptors may function as a potent in-
hibitor of the TNF- . α
37,38 Despite the significant
data concerning the function of sTNFRs as inhi-
bitors of TNF- activity, other reports show that α
when sTNFR concentrations are low, sTNFR may
increase TNF- activity by stabilizing the TNF- α α
trimeric structure and prolonging its availability
for membrane receptor binding.
39,40 We deter-
mined the levels of soluble TNFR1 (sTNFR1) and
sTNFR2 in the astrocyte culture supernatant using
ELISA. The level of sTNFR1 was found to increase
gradually over a 72 h period, whereas sTNFR2
was not detectable. These results indicate that
human astrocytes constitutively shed TNFR1
under normal conditions, which may be respon-
sible for the weak expression of TNFR1 on the
cellular surface. sTNFR1 is 5-30 times more potent
than sTNFR2 in vitro and is also a better inhibitor
of TNF- activity α in vivo.
38,41,42 sTNFR1 secreted by
astrocytes may participate in the control of TNF-α
activity in the human brain. Further study con-
cerning the physiologic role of sTNFR1 shed from
astrocytes should be continues.
In the present study, we have shown that
TNFR2 is selectively upregulated by IL-1 , TNF- , β α
or IFN- treatment in astrocytes, while LPS does γ
not affect TNFR2 mRNA expression. In contrast,
the TNFR1 transcript was found to maintain a
constant level throughout the various cytokine
treatments. The TNF receptor has been shown to
be differentially regulated in various cell types,
and similar modulation has been observed in
epithelioid cells and in a fibroblast cell line for
TNF- and IL-1 . α β
20 These results differ from those
of a previous report, which found that TNF-α
upregulates only TNFR1 in rat astrocytes andSun Ju Choi, et al.
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human epithelial cells.
32 However, our results are
consistent with the finding that TNF-α
upregulates only TNFR2 in rat primary
astrocytes.
27 This difference may be attributed to
the particular species or to the experimental
method used. It is generally believed that TNFR1
mediates cytotoxicity, whereas TNFR2 mediates a
mitogenic effect.
12 Moreover, Selmaj et al. reported
that both TNF- and IL-6 act on astrocyte α
proliferation.
24,43 Taken together with the current
findings, it is possible that the proliferative effect
of TNF- on astrocytes might be mediated α
through the upregulation of TNFR2. Further
studies should be undertaken to define the
significance of TNFR2 upregulation by cytokines.
It has also been reported that exogenous TNF-α
can induce TNF- expression and NF- B activa α κ -
tion.
10 Because TNFR2 has been shown to be
involved in NF-κB activation,
44 the fact that TNFR
1 is a predominantly expressed receptor on astro-
cytes does not necessarily prove that it is a the
major signal transducing receptor for NF-κB
activation. To determine which receptor is re-
sponsible for the NF-κB activation and the TNF-α
expression, we used neutralizing antibodies
against TNFR1 and TNFR2. The induction of TNF-
and NF- α κB activation was inhibited using a
neutralizing anti-TNFR1 antibody. These results
suggest that the effects of TNF- on NF- α κB activa-
tion and TNF- induction are mediated by TNFR1 α
in human astrocytes. In conclusion, the present
study shows that TNFR1 is a predominantly
transcribed and translated TNF receptor in human
astrocytes and is constitutively shed from the
cellular surface. Moreover, the study shows that
TNFR1 functions in NF-κB activation and TNF-α
induction. Although the expression of TNFR2 was
at a very low level under normal conditions, it
was increased by TNF- , IL-1, or IFN- treatment. α γ
Further studies should be undertaken to define
the significance of TNFR2 upregulation by cyto-
kines and the physiologic role of the sTNFR1
secreted by human astrocytes.
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